NKTR Nektar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: NKTR

Price (delayed)

$0.718

Market cap

$135.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.97

Enterprise value

$179.14M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
Nektar Therapeutics's EPS has increased by 31% YoY and by 19% QoQ
The net income has grown by 30% year-on-year and by 19% since the previous quarter
Nektar Therapeutics's quick ratio has decreased by 16% YoY but it has increased by 13% from the previous quarter
Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ
The revenue has contracted by 10% YoY and by 3.1% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nektar.com
Peers: PFE MRK AMGN ENZN

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
189.24M
Market cap
$135.87M
Enterprise value
$179.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
1.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.95
Earnings
Revenue
$92.06M
EBIT
-$336.07M
EBITDA
-$323.04M
Free cash flow
-$296.49M
Per share
EPS
-$1.97
Free cash flow per share
-$1.58
Book value per share
$1.95
Revenue per share
$0.49
TBVPS
$3.39
Balance sheet
Total assets
$710.6M
Total liabilities
$343.96M
Debt
$131.5M
Equity
$366.64M
Working capital
$477.76M
Liquidity
Debt to equity
0.36
Current ratio
8
Quick ratio
7.49
Net debt/EBITDA
-0.13
Margins
EBITDA margin
-350.9%
Gross margin
76.5%
Net margin
-400%
Operating margin
-408.6%
Efficiency
Return on assets
-43.6%
Return on equity
-79.8%
Return on invested capital
-46.1%
Return on capital employed
-52.3%
Return on sales
-365.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-3.38%
1 week
-26.74%
1 month
-51.81%
1 year
-87.77%
YTD
-68.23%
QTD
-68.23%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$92.06M
Gross profit
$70.42M
Operating income
-$376.17M
Net income
-$368.2M
Gross margin
76.5%
Net margin
-400%
The net income has grown by 30% year-on-year and by 19% since the previous quarter
The net margin has increased by 22% YoY and by 16% QoQ
The operating income is up by 16% year-on-year and by 14% since the previous quarter
The operating margin has grown by 11% from the previous quarter and by 7% YoY

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
0.37
P/S
1.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.95
Nektar Therapeutics's EPS has increased by 31% YoY and by 19% QoQ
The P/B is 98% below the 5-year quarterly average of 17.6 and 75% below the last 4 quarters average of 1.5
Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ
The stock's P/S is 93% less than its 5-year quarterly average of 21.0 and 79% less than its last 4 quarters average of 7.0
The revenue has contracted by 10% YoY and by 3.1% from the previous quarter

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has decreased by 29% YoY but it has increased by 5% from the previous quarter
Nektar Therapeutics's return on sales has increased by 22% YoY and by 18% QoQ
The return on invested capital has declined by 12% year-on-year but it has grown by 8% since the previous quarter
NKTR's ROA is up by 9% from the previous quarter but it is down by 9% YoY

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 107% more than its total liabilities
Nektar Therapeutics's total assets has decreased by 36% YoY and by 9% from the previous quarter
The total liabilities has contracted by 21% YoY and by 7% from the previous quarter
The debt is 64% lower than the equity
The debt to equity has soared by 71% YoY and by 9% QoQ
Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.